114 Les biomarqueurs moléculaires en oncologie
25. Goetz MP, Suman VJ, Hoskin TL, et al. (2013) CYP2D6 Metabolism and Patient Outcome
in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8. Clin Cancer
Res. Jan 15;19(2): 500-7.
26. Wegman P, Elingarami S, Carstensen J, et al. (2007) Genetic variants of CYP3A5,
CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with
breast cancer. Breast Cancer Res.;9(1): R7.
27. Rae JM, Drury S, Hayes DF, et al. (2012) CYP2D6 and UGT2B7 genotype and risk of
recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst. Mar 21;104(6):
452-60.
28. Regan MM, Leyland-Jones B, Bouzyk M, et al. (2012) CYP2D6 genotype and tamoxifen
response in postmenopausal women with endocrine-responsive breast cancer: the breast
international group 1-98 trial. J Natl Cancer Inst. Mar 21;104(6): 441-51.
29. Province MA, Klein TE; International Tamoxifen Pharmacogenomics Consortium (2014).
CYP2D6 genotyping and the use of tamoxifen in breast cancer. J Natl Cancer Inst.
Feb;106(2): 216-27.
30. Warmerdam PA, van de Winkel JG, Vlug A, et al. (1991) A single amino acid in the second
Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. J
Immunol. Aug 15;147(4): 1338-43.
31. Cartron G, Dacheux L, Salles G, et al. (2002) Therapeutic activity of humanized antiCD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.
Blood. 2002 Feb 1;99(3): 754-8.
32. Weng WK, Levy R. (2003) Two immunoglobulin G fragment C receptor polymorphisms
independently predict response to rituximab in patients with follicular lymphoma. J Clin
Oncol; 21: 3940-3947.
33. Musolino A, Naldi N, Bortesi B, et al. (2008) Immunoglobulin G fragment C receptor
polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/
neu-positive metastatic breast cancer. J Clin Oncol. Apr 10;26(11): 1789-96.
34. Tamura K, Shimizu C, Hojo T, et al. (2011) FcaR2A and 3A polymorphisms predict
clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients
with HER2-positive breast cancer. Ann Oncol. Jun;22(6): 1302-7.
35. Hurvitz SA, Betting DJ, Stern HM, et al. (2012) Analysis of Fca receptor IIIa and IIa
polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer
patients. Clin Cancer Res. Jun 15;18(12): 3478-86.
36. Zhang W, Gordon M, Schultheis AM, et al. (2007) FCGR2A and FCGR3A polymorphisms
associated with clinical outcome of epidermal growth factor receptor expressing metastatic
colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. Aug
20;25(24): 3712-8.
37. Lurje G, Nagashima F, Zhang W, et al. (2008) Polymorphisms in cyclooxygenase-2 and
epidermal growth factor receptor are associated with progression-free survival independent
of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. Clin
Cancer Res. Dec 1;14(23): 7884-95.
38. Bibeau F, Lopez-Crapez E, Di Fiore F, et al. (2009) Impact of FcgRIIa-FcgRIIIa
polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic
colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol. Mar 1;27(7):1122-9.
39. Pander J, Gelderblom H, Antonini NF, et al. (2010) Correlation of FCGR3A and EGFR
germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic
colorectal cancer. Eur J Cancer. Jul;46(10):1829-34.
40. Etienne-Grimaldi MC, Bennouna J, Formento JL, et al. (2012) Multifactorial
pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based
therapy together with cetuximab-irinotecan. Br J Clin Pharmacol. May;73(5):776-85.
25. Goetz MP, Suman VJ, Hoskin TL, et al. (2013) CYP2D6 Metabolism and Patient Outcome
in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8. Clin Cancer
Res. Jan 15;19(2): 500-7.
26. Wegman P, Elingarami S, Carstensen J, et al. (2007) Genetic variants of CYP3A5,
CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with
breast cancer. Breast Cancer Res.;9(1): R7.
27. Rae JM, Drury S, Hayes DF, et al. (2012) CYP2D6 and UGT2B7 genotype and risk of
recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst. Mar 21;104(6):
452-60.
28. Regan MM, Leyland-Jones B, Bouzyk M, et al. (2012) CYP2D6 genotype and tamoxifen
response in postmenopausal women with endocrine-responsive breast cancer: the breast
international group 1-98 trial. J Natl Cancer Inst. Mar 21;104(6): 441-51.
29. Province MA, Klein TE; International Tamoxifen Pharmacogenomics Consortium (2014).
CYP2D6 genotyping and the use of tamoxifen in breast cancer. J Natl Cancer Inst.
Feb;106(2): 216-27.
30. Warmerdam PA, van de Winkel JG, Vlug A, et al. (1991) A single amino acid in the second
Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. J
Immunol. Aug 15;147(4): 1338-43.
31. Cartron G, Dacheux L, Salles G, et al. (2002) Therapeutic activity of humanized antiCD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.
Blood. 2002 Feb 1;99(3): 754-8.
32. Weng WK, Levy R. (2003) Two immunoglobulin G fragment C receptor polymorphisms
independently predict response to rituximab in patients with follicular lymphoma. J Clin
Oncol; 21: 3940-3947.
33. Musolino A, Naldi N, Bortesi B, et al. (2008) Immunoglobulin G fragment C receptor
polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/
neu-positive metastatic breast cancer. J Clin Oncol. Apr 10;26(11): 1789-96.
34. Tamura K, Shimizu C, Hojo T, et al. (2011) FcaR2A and 3A polymorphisms predict
clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients
with HER2-positive breast cancer. Ann Oncol. Jun;22(6): 1302-7.
35. Hurvitz SA, Betting DJ, Stern HM, et al. (2012) Analysis of Fca receptor IIIa and IIa
polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer
patients. Clin Cancer Res. Jun 15;18(12): 3478-86.
36. Zhang W, Gordon M, Schultheis AM, et al. (2007) FCGR2A and FCGR3A polymorphisms
associated with clinical outcome of epidermal growth factor receptor expressing metastatic
colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. Aug
20;25(24): 3712-8.
37. Lurje G, Nagashima F, Zhang W, et al. (2008) Polymorphisms in cyclooxygenase-2 and
epidermal growth factor receptor are associated with progression-free survival independent
of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. Clin
Cancer Res. Dec 1;14(23): 7884-95.
38. Bibeau F, Lopez-Crapez E, Di Fiore F, et al. (2009) Impact of FcgRIIa-FcgRIIIa
polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic
colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol. Mar 1;27(7):1122-9.
39. Pander J, Gelderblom H, Antonini NF, et al. (2010) Correlation of FCGR3A and EGFR
germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic
colorectal cancer. Eur J Cancer. Jul;46(10):1829-34.
40. Etienne-Grimaldi MC, Bennouna J, Formento JL, et al. (2012) Multifactorial
pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based
therapy together with cetuximab-irinotecan. Br J Clin Pharmacol. May;73(5):776-85.